Table 4.
Annual platelet costs, reimbursement, and shelf life
| 100% C-PC (US$) | 100% RT-PC (US$) | 100% PR-PC (US$) | 50% RT-PC/50% PR-PC (US$) | |
|---|---|---|---|---|
| Acquisition | 3,192,540 | 3,192,540 | 3,527,680 | 3,360,110 |
| RT costs | 0 | 121,890 | 0 | 60,945 |
| Wastage | 182,067 | 86,565 | 167,644 | 127,104 |
| Dispensing/transfusion | 260,721 | 260,721 | 260,721 | 260,721 |
| Sepsis (excludes septic shock cases that result in MODs/mortality/morbidity) | 7289 | 7289 | 0 | 3645 |
| Total annual cost | 3,642,617 | 3,669,005 | 3,956,045 | 3,812,525 |
| Outpatient reimbursement | 895,238 | 922,347 | 1,037,508 | 979,927 |
| Total hospital cost (less reimbursement) | 2,747,379 | 2,746,658 | 2,918,537 | 2,832,598 |
| Percentage of blood budgeta | 2.11 | 2.11 | 2.24 | 2.18 |
| PC age when placed in inventory (h) | 48 | 48 | 33 | NA |
| Maximum usable shelf life (h) | 72 | 120 | 87 | NA |
aAssumes an annual blood budget of US$130 million, including platelet, plasma, and red blood cell components
C-PC conventional platelet component, RT-PC rapid-tested platelet component, PR-PC pathogen-reduced platelet component, RT rapid testing, MODs multiple organ dysfunction syndrome, PC platelet component, NA not applicable